Georgia allows psilocybin for medical research

The Georgia Legislature approved file HB382 ("Georgia allows psilocybin for medical research"), by a recorded vote of 205 to 10. Last action: May 11, 2026.

Georgia file HB382, before the Georgia Legislature. Passed as of 2026-05-11.

What it does

Psilocybin penalties may shift based on new scheduling The bill modifies Code Section 16-13-25 governing Schedule I controlled substances; without the bill text specifying the exact revision, the direct effect on possession penalties, prosecution thresholds, or medical/research exceptions remains unclear but will take effect upon gubernatorial signature.

The bigger picture

Could open door to future research or medical programs Reclassifying or narrowing psilocybin's Schedule I status may align Georgia with emerging state-level clinical trials and mental health research initiatives underway in other jurisdictions.

What to watch

Federal law conflict and enforcement uncertainty ahead Psilocybin remains a Schedule I substance under federal law; Georgia's revision could create a conflict zone where state and federal enforcement priorities diverge, and law enforcement agencies may face ambiguity during the implementation period.

Official summary

A BILL to be entitled an Act to amend Code Section 16-13-25 of the Official Code of Georgia Annotated, relating to Schedule I controlled substances, so as to revise a provision relating to psilocybin; to provide for related matters; to repeal conflicting laws; and for other purposes.

How they voted

Yes (205)

No (10)

Did not vote / other (15)

See everything up for a vote · This week in Georgia · See what we have filed with the clerk